• PDF / 115,360 Bytes
• 6 Pages / 612.28 x 790.87 pts Page_size
• 40 Downloads / 196 Views

DOWNLOAD

REPORT

Mol Diagn Ther 2011; 15 (1): 57-62 1177-1062/11/0001-0057/$49.95/0

ª 2011 Adis Data Information BV. All rights reserved.

From the Literature Case Reportsy

Contents 1. 2. 3. 4. 5. 6.

Antineoplastics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cardiovascular Therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Endocrine Therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Immunosuppressants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Neurologic and Psychiatric Therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1. Antineoplastics Rituximab: Neutropenia: Nine Case Reports

Nine patients (five women and four men), aged between 49 and 84 years, developed late-onset neutropenia between 30 and 138 days after completing rituximab therapy for diffuse large B-cell lymphoma. In addition to rituximab, the patients were also administered either cyclophosphamide, epirubicin, vincristine, and prednisolone (R-CEOP); or etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (R-EPOCH); or cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP); or etoposide, cytarabine, cisplatin, and methylprednisolone (R-ESHAP). The lowest absolute neutrophil count values were between 210 · 109/L and 1240 · 109/L. Neutropenia resolved in all patients after 7 to 329 days. Author Comment: ‘‘[T]he FcgRIIIa 158 V/V and V/F polymorphism was significantly associated with development of rituximab-related [late onset neutropenia] in newly-diagnosed B-cell lymphoma.’’ Li SC, Chen YC, Evens AM, et al. Rituximab-induced late-onset neutropenia in newly-diagnosed B-cell lymphoma correlates with Fc receptor Fc-gamma-RIIIa 158(V/F) polymorphism. Am J Hematol 2010; 85: 810-2

57 59 60 60 61 62

Erlotinib/Gemcitabine: Complete Response in a Patient with Gallbladder Cancer with No Activating EGFR Mutation: Case Report

A 67-year-old man with metastatic gallbladder adenocarcinoma commenced the epidermal growth factor receptor (EGFR)tyrosine kinase inhibitor (TKI) erlotinib [Tarceva] 100 mg/day and gemcitabine [Gemzar] 1000 mg/m2 at a rate of 10 mg/m2/min on days 1 and 8 every 21 days. After six cycles, there was no evidence of resid

Recommend Documents

From the Literature

164 80 121KB

From the Literature

175 1 112KB

From the Literature

154 11 140KB

From the Literature

147 67 189KB

From the Literature

170 84 122KB

From the Literature

162 18 145KB

From the World Literature

169 111 105KB

From Literature to Cultural Literacy

181 25 3MB

Is the literature inconclusive about the harm from HES? No

172 110 919KB

The Legacy of Courtly Literature From Medieval to Contemporary Cultu

201 39 3MB

Benefitting from the Grey Literature in Software Engineering Research

167 55 13MB

Utopian Literature and Science From the Scientific Revolution to Bra

186 108 1MB